| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
208,280,000 |
| Market
Cap: |
1.96(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.09 - $15.86 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a cross-functional team to discover medicines. Co.'s potential medicines include: REC-994 for the treatment of cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 for the treatment of familial adenomatous polyposis; REC-3599 for the treatment of GM2 gangliosidosis; REC-3964 for the treatment of C. difficile colitis; REC-64917 for neural or systemic inflammation; and multiple simultaneous programs in fibrosis developing with Bayer AG.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,693,990 |
| Total Buy Value |
$0 |
$0 |
$0 |
$12,897,789 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
27 |
| Total Shares Sold |
588,000 |
1,097,598 |
2,193,115 |
3,020,700 |
| Total Sell Value |
$5,667,181 |
$10,572,222 |
$21,602,157 |
$28,825,014 |
| Total People Sold |
4 |
7 |
8 |
8 |
| Total Sell Transactions |
24 |
46 |
97 |
149 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bogue Zachary |
Director |
– • • |
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
4,012 |
|
- |
|
| Burrell Terry-Ann |
Director |
– • – |
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,631 |
156,149 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-06-21 |
4/A |
GD |
$0.00 |
$0 |
D/D |
3,000 |
582,805 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-06-21 |
4/A |
A |
$0.00 |
$0 |
D/D |
3,000 |
585,805 |
|
- |
|
| Chavez R Martin Phd |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,145 |
29,252 |
|
- |
|
| Dar Zavain |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,145 |
18,145 |
|
- |
|
| Burrell Terry-Ann |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,145 |
154,518 |
|
- |
|
| Li Dean Y |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,145 |
617,611 |
|
- |
|
| Hershberg Robert |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,145 |
26,007 |
|
- |
|
| Borgeson Blake |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,145 |
7,670,591 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-06-02 |
4 |
AS |
$6.34 |
$15,859 |
I/I |
(2,500) |
0 |
|
68% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,500 |
1,000 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-06-02 |
4 |
AS |
$5.87 |
$241,766 |
D/D |
(39,690) |
516,268 |
|
68% |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
18,500 |
534,768 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-06-02 |
4 |
OE |
$2.48 |
$77,500 |
D/D |
31,250 |
537,458 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-05-19 |
4/A |
GD |
$0.00 |
$0 |
D/D |
12,000 |
582,805 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-05-19 |
4/A |
A |
$0.00 |
$0 |
D/D |
12,000 |
594,805 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-05-16 |
4 |
D |
$5.67 |
$32,682 |
D/D |
(5,764) |
506,208 |
|
- |
|
| Doyle Ramona |
Chief Medical Officer |
• – – |
2022-05-16 |
4 |
D |
$5.67 |
$4,717 |
D/D |
(832) |
121,110 |
|
- |
|
| Secora Michael |
Chief Financial Officer |
• – – |
2022-05-16 |
4 |
D |
$5.67 |
$6,061 |
D/D |
(1,069) |
588,702 |
|
- |
|
| Virani Shafique |
Chief Corp. Dev. Officer |
• – – |
2022-05-16 |
4 |
D |
$5.67 |
$4,933 |
D/D |
(870) |
104,386 |
|
- |
|
| Larson Tina Marriott |
President and COO |
• – – |
2022-05-16 |
4 |
D |
$5.67 |
$8,267 |
D/D |
(1,458) |
206,560 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-05-12 |
4/A |
GD |
$0.00 |
$0 |
D/D |
12,000 |
582,805 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-05-12 |
4/A |
A |
$0.00 |
$0 |
D/D |
12,000 |
594,805 |
|
- |
|
| Gibson Christopher |
Chief Executive Officer |
• • – |
2022-04-29 |
4 |
AS |
$6.30 |
$15,767 |
I/I |
(2,500) |
0 |
|
114% |
|
618 Records found
|
|
Page 17 of 25 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.09 (0.95%) 
